The Potential Relevance of the Multiple Lipid-Independent (Pleiotropic) Effects of Statins in the Management of Acute Coronary Syndromes  by Ray, Kausik K. & Cannon, Christopher P.
FT
L
i
K
B
A
n
e
b
t
p
b
e
(
i
t
(
l
r
H
m
i
L
L
t
o
e
r
r
R
a
Journal of the American College of Cardiology Vol. 46, No. 8, 2005
© 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00
POCUS ISSUE: PROVE IT-TIMI 22 State-of-the-Art Paper
he Potential Relevance of the Multiple
ipid-Independent (Pleiotropic) Effects of Statins
n the Management of Acute Coronary Syndromes
ausik K. Ray, MRCP, MD, Christopher P. Cannon, MD, FACC
oston, Massachusetts
Emerging data suggest that acute presentations of coronary artery disease may involve a
complex interplay between the vessel wall, inflammatory cells, and the coagulation cascade.
Although a culprit thrombotic lesion may be treated effectively by antithrombotic therapy and
revascularization, this will have little effect on the global processes that determine recurrent
events at non-culprit sites. Thus, additional systemic treatment is required to modulate the
adverse biological features that are the hallmark of acute coronary syndromes (ACS). Statins
possess multiple beneficial effects that are independent of low-density-lipoprotein cholesterol
(LDL-C) lowering and that have favorable effects on inflammation, the endothelium, and the
coagulation cascade. In the Pravastatin or Atorvastatin Evaluation and Infection Therapy–
Thrombolysis In Myocardial Infarction 22 (PROVE IT-TIMI 22) trial, differences were seen
based on achieved LDL-C that could be further discriminated by the achieved C-reactive
protein level. Studies of non-vascular disease such as multiple sclerosis have shown that statins
reduce inflammation, supporting the presence of lipid-independent effects of statins. This
review focuses on the potential importance of these effects in the management of
ACS. (J Am Coll Cardiol 2005;46:1425–33) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.086Cardiology Foundation
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Tcute coronary syndromes (ACS) are increasingly recog-
ized to be secondary to a diffuse process involving the
ntire coronary vasculature (1). Although multiple vulnera-
le or ruptured plaques may be present at a given point in
ime, only a few of these ultimately lead to an acute
resentation. It is now suggested that a complex interplay
etween the pathological vascular triad of inflammation,
ndothelial dysfunction/activation, and thrombosis exists
Fig. 1) that individually or collectively determines an
ndividual’s propensity to develop an ACS. Statins inhibit
he enzyme 3-hydroxy-3-methylglutaryl coenzyme A
HMG-CoA) reductase, which is central not only to cho-
esterol metabolism (via the liver) but which also plays a key
ole in cell signaling in many vascular cells. Inhibition of
MG-CoA reductase in vascular cells by statins rapidly
odulates a number of cellular responses implicated in ACS
n a dose-dependent manner.
IPID-DEPENDENT EFFECTS OF STATINS
ow-density lipoprotein-C (LDL-C) is intrinsically linked
o atherothrombosis and is oxidized by free radicals to
xidized LDL-C (ox-LDL-C), which in turn has a number
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ccepted May 16, 2005.f deleterious effects. Hence, reductions in the circulating
DL-C pool will likely reduce the amount of the LDL-C
ubstrate available for oxidation and therefore potentially
ave beneficial early effects (2). Non-statin therapies that
ower LDL-C, such as ileal bypass or use of bile acid
equestrants, require five to seven years to show a clinical
ffect, in contrast to the earlier benefits observed in statin
rials (3). Although statins reduce LDL-C and markers of
nflammation such as C-reactive protein (CRP), the corre-
ation coefficient between LDL-C and CRP is weak (ap-
roximately 0.13) (4), suggesting that the reductions in
RP cannot be explained by reductions in LDL-C alone.
dditionally, patients receiving statins have lower event
ates than that predicted by their achieved LDL-C, raising
he possibility of distinct mechanisms beyond cholesterol
eduction (cholesterol-independent effects). Moreover,
hese lipid-independent effects may be particularly relevant
o the early benefit in ACS. In the A to Z trial, an intensive
tatin regimen was associated with a 60-mg/dl LDL-C
ifference at four months, but no clinical benefit was seen
and no CRP difference was shown at one month). In
ontrast, the Pravastatin or Atorvastatin Evaluation and
nfection Therapy–Thrombolysis In Myocardial Infarction
2 (PROVE IT-TIMI 22) trial had less LDL-C difference
32 mg/dl) but a greater CRP difference and early benefit
5). These data suggest strongly that the early benefits of
tatins in ACS are mediated by a lipid-independent process.
he LDL-C–dependent benefits of statins are summarized
n Table 1.
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nhibition of HMG-CoA reductase by statins inhibits the
eneration of proteins called isoprenoids (geranyl-geranyl
yrophosphate and farnesyl pyrophosphate) in vascular cells
Fig. 2). The binding of isoprenoids to a number of
ignaling proteins (Rho and Ras) enables them to function
n inflammatory signaling pathways. Rho activates a number
f nuclear transcription factors such as nuclear factor-kappa
, which promote a number of inflammatory responses, and
lso reduces endothelial nitric oxide synthetase, which serves
s a protective factor in vascular disease. Statins promote
nti-inflammatory pathways by inhibiting Rho, and also by
p-regulating endothelial nitric oxide synthetase. The lipid-
ndependent, diverse biological effects produced by the
nhibition of isoprenoid synthesis have been collectively
eferred to as pleiotropic effects. As this review shows, this
erm may be an oversimplification because statins have
istinct effects on each component of the vascular triad
mplicated in atherothrombosis (Fig. 1, Table 1).
HE ENDOTHELIUM IN ACS
he normal endothelium synthesizes nitric oxide (NO),
hich gives the vessel wall its vasodilator and antithrom-
otic properties (6). Under resting conditions, the endothe-
ium presents a non-adherent surface expressing very little in
he way of adhesion molecules such as E-selectin and
ntercellular adhesion molecule (ICAM)-1. The surface is
lso non-thrombotic, expressing high levels of thrombo-
odulin (TM) and small amounts of tissue factor (TF). A
mall amount of von Willebrand factor (vWF) is constitu-
ively released, and the net balance of tissue plasminogen
ctivator (tPA)/plasminogen activator inhibitor (PAI-1)
avors fibrinolysis (6).
Endothelial dysfunction is an independent predictor of
Abbreviations and Acronyms
ACS  acute coronary syndromes
CAD  coronary artery disease
CRP  C-reactive protein
HMG-CoA  3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA)
ICAM  intercellular adhesion molecule
IL  interleukin
LDL-C  low-density lipoprotein
cholesterol
NO  nitric oxide
PAI-1  plasminogen activator inhibitor
PROVE IT-TIMI 22  Pravastatin or Atorvastatin
Evaluation and Infection
Therapy–Thrombolysis In
Myocardial Infarction 22
TF  tissue factor
TM  thrombomodulin
tPA  tissue plasminogen activator
vWF  von Willebrand factorlinical risk in patients with coronary artery disease (CAD).
F
dhe normal endothelium is distorted in ACS (Fig. 3). In
esponse to inflammatory cytokines, the endothelium down-
egulates TM and up-regulates TF. There is also enhanced
elease of vWF and a reduction in the tPA/PAI-1 ratio,
hich combined with the reduction in NO release favors
hrombosis and vasoconstriction. Increased local expression
f adhesion molecules on the endothelial surface (7), to-
ether with increased local levels of chemoattractants (e.g.,
onocyte chemoattractant protein-1 [MCP-1]), result in
he adhesion and transmigration of inflammatory cells to
otentially vulnerable sites within the vessel wall (8). Here,
nflammatory cells can further propagate inflammation
hrough the release of inflammatory cytokines. Acute cor-
nary sydrome is associated with elevations in soluble
arkers of endothelial activation such as vWF, E-selectin,
nd ICAM-1, and a reduction in these markers seems to
orrelate with a reduction in cardiovascular mortality/
orbidity (9). Hence, treatments that lead to a reduction in
ndothelial activation may be biologically beneficial.
FFECT OF STATINS ON
NDOTHELIAL ACTIVATION/FUNCTION
tatins have beneficial effects on endothelial function inde-
endently of effects on lipid lowering, and these are related
o a rapid increase in NO bioavailability (10). In stable
atients, improvements in flow-mediated dilatation have
een observed as early as three hours (11), i.e., well before
he effects of hepatic HMG-CoA reductase inhibition areigure 1. “Pathological vascular triad” implicated in acute coronary syn-
rome. Illustration by Rob Flewell.
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October 18, 2005:1425–33 Lipid-Independent Effects of Statins in ACSikely to have impacted on plasma LDL-C. Statins also
educe the endothelial expression of endothelin-1 (12),
urther favoring vasodilatation. Because CRP reduces
-NOS and impairs flow-mediated dilatation (13), some of
he beneficial effects on endothelial function may be indi-
ectly mediated by the ability of statins to lower CRP.
Erosion of the endothelial surface and exposure to circu-
ating blood may trigger thrombosis, and patients with
ighest circulating coagulation factors are at greatest risk.
epair of the damaged endothelium is therefore important,
nd may occur in two ways: firstly by migration of adjacent
ndothelial cells or secondly from mobilization of circulat-
ng endothelial progenitor cells derived from the bone
arrow. Statins increase the number and the survival of
irculating endothelial progenitor cells, and mobilize them
o sites of injury (14), thus accelerating re-endothelialization
15) as rapidly as one week after treatment (16). Senescence
f endothelial progenitor cells contributes to reduced endo-
helial reparative capacity. Statins also inhibit senescence
nd increase cell proliferation by effects on cell cycle genes
17), hence statins may reduce recurrent events at sites of
uperficial erosions by having favorable effects on cellular
epair.
In large prospective studies of patients with CAD,
levations in levels of adhesion molecules predict adverse
linical events in a manner analogous to that of CRP (18).
tatins reduce the expression of adhesion molecules such as
-selectin and ICAM-1 on the surface of endothelial cells
n response to various stimuli, at the level of gene transcrip-
able 1. Pathways By Which Statins Can Modulate the Patholog
HMG-CoA Reductase Dependen
Cholesterol Dependent Chol
LDL-C and 2 oxidized LDL-C 2Prenylation
2 Isoprenoid synthes
Down-regulation of R
2 NFB and inflamm
Foam cell formation 2 Expression of MC
Macrophage number 2 Binding of lympho
Cholesterol rafts for inflammatory signalling Down-regulation of T
Expression of inflammatory cytokines Cytokine switching fro
lymphocytes
2 Inflammatory cytok
modulation
Nitric oxide levels by stabilizing m-RNA 1 Nitric oxide produ
Oxidative stress 2 Oxidative stress
Expression of adhesion molecules 2 Endothelial adhesi
Platelet activation 1 Increased TM expr
2 Tissue factor expre
1 tPA/PAI-1 ratio
2 Coagulation factor
CS  acute coronary syndromes; CRP  C-reactive protein; HMG-CoA  3-hyd
ow-density lipoprotein cholesterol; MCP  monocyte chemoattractant protein;
hrombomodulin; tPA  tissue plasminogen activator.ion (19), resulting in fewer inflammatory cells binding to an tctivated endothelium and thus increasing the stability of
ulnerable plaques. In small clinical studies, statins have
een shown to reduce circulating levels of adhesion mole-
ules (20). Therefore, part of the cardiovascular benefit of
tatins may be mediated by reducing the activation of the
ndothelium.
The endothelium produces a number of inflammatory
ytokines that may activate inflammatory cells and platelets,
ncluding interleukin (IL)-1, IL-6, and CD40 ligand and its
eceptor (CD40). In endothelial cells, statins reduce IL-1
nd IL-6 production at the level of gene transcription (21),
nd also the expression of CD40 ligand and CD40, sug-
esting that statins play a potent role in mediating inflam-
ation within endothelial cells by directly reducing local
ytokine production or by inhibiting cytokine binding
22,23) (Table 2).
ROTHROMBOTIC CHANGES IN ACS
nflammation is intrinsically related to ACS and results in a
own-regulation of TM and up-regulation of TF on the
urface of the endothelium, favoring thrombosis. A reduc-
ion in circulating soluble TM has been implicated in the
evelopment of incident CAD (24), and recently circulating
F has emerged as a possible risk factor for ACS, with
bservations that classical risk factors and ACS are associ-
ted with higher TF levels (25,26). Elevated fibrinogen and
actor VII levels have been associated with increased car-
iovascular risk in stable and unstable CAD (27,28). Thus,
Changes in ACS
HMG-CoA Reductase
Independentol Independent
okinase
signalling
y endothelial cells Binding to the lymphocyte function
associated antigen, thus
preventing binding of lymphocyte
to endothelial counter ligand
ICAM-1
to endothelial receptor ICAM-1
ymphocytes
h-1 to Th-2 type phenotype in
roduction/CRP immune
lecule expression
? Inactivation of factor Va
-methylglutaryl coenzyme A; ICAM  intercellular adhesion molecule; LDL-C 
B  nuclear factor kappa B; PAI  plasminogen activator inhibitor; TM ical
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Lipid-Independent Effects of Statins in ACS October 18, 2005:1425–33atural anticoagulants would be expected to have favorable
ffects on thrombosis.
FFECT OF STATINS ON MARKERS OF COAGULATION
tatins increase TM expression on the cell surface (29) and
educe TF expression on endothelial cells directly by inhib-
ting the Rho/Rho kinase pathways (30). This not only
educes thrombin generation, but the binding of thrombin
o TM also activates protein C, stimulating the intrinsic
nticoagulation cascade. In addition, statin therapy reduces
irculating levels of vWF (31) and tends to alter the balance
f PAI-1 to tPA back in favor of fibrinolysis (32), possibly
ia the reduction in circulating levels of proinflammatory
ytokines as an intermediate step. CD40 ligand and CRP
re powerful inducers of tissue factor expression by the
onocyte/macrophage system, and a reduction in these
ediators by statins could result in a second, indirect
ethod by which statins could reduce TF (33).
In addition to effects mediated by the vessel wall, statins
ave systemic effects on coagulation, including reductions in
actor VII antigen levels (34), prothrombin activation, factor
igure 2. Molecular pathway. Inhibition of 3-hydroxy-3-methylglutaryl co
roduction (geranyl-geranyl pyrophosphate and farnesyl pyrophosphate). T
inding. Illustration by Rob Flewell.a generation, and factor XIII activation, as well as an cncreased rate of factor Va inactivation (35). The mecha-
isms behind this are unclear, but could reflect an effect on
rotein transcription within the liver, the activation of
atalytic enzymes, both, or some other mechanism yet to be
dentified. These effects are cholesterol-independent and
ay serve to reduce clot formation or the stability of fibrin
lots. These data suggest that statins improve markers of
oagulation by both endothelium-dependent and non-
ndothelium-dependent mechanisms (Table 2).
HE ROLE OF INFLAMMATION IN ACS
atients with ACS have heightened focal inflammation
ithin the vessel wall as well as evidence of a systemic
nflammatory response (summarized in Table 3). In partic-
lar, T-lymphocytes present in the plaque produce a num-
er of inflammatory proteins (cytokines), including inter-
eron (IFN)-gamma, which lead to a decrease in collagen
roduction by vascular smooth muscle cells. Activated
acrophages produce large quantities of matrix metallopro-
einases and elastases, which degrade collagen and elastin,
esulting in a weakening of the fibrous cap. In the systemic
e A (HMG-CoA) reductase inhibits cholesterol synthesis and isoprenoid
turn reduces prenylation of G proteins such as Rho, and hence membraneenzymirculation, evidence of immune activation also can be
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October 18, 2005:1425–33 Lipid-Independent Effects of Statins in ACSbserved (Fig. 4) (36–40), resulting in the production of
roinflammatory cytokines (Table 1). Suppressing the ac-
ivity of inflammatory cells therefore represents an impor-
ant therapeutic target for the management of ACS (Fig. 4).
Acute coronary syndrome is associated with an increase in
on-specific markers of systemic inflammation, such as CRP,
igure 3. Endothelial abnormalities in acute coronary syndrome. ET  en
lasminogen activator inhibitor; t-PA  tissue plasminogen activator; TF
olecule. Illustration by Rob Flewell.
able 2. Endothelial and Coagulation Abnormalities Implicated
n ACS and the Effect of Statins on Endothelial and
oagulation Markers
Health
Changes
Implicated
in ACS
Effect of
Statins
ndothelial function
Vasomotor function 1 2 1
NO bioavailability 1 2 1
eNOS 1 2 1
ndothelial activation
Adhesion molecule expression 2 1 2
ndothelial repair
Progenitor cell number 1 2 1
Progenitor cell senescence 2 1 2
oagulation
Tissue factor 2 1 2
Thrombomodulin 1 2 1
PAI-1 2 1 2
tPA 1 2 1
vWF 2 1 2
actor VII 2 1 2
a 2 Unknown 2r
NOS  endothelial nitric oxide synthetase; NO  nitric oxide; vWF  von
illebrand factor. Other abbreviations as in Table 1.nd those with the highest levels have the worst clinical
utcomes (41). Hepatic production of CRP is largely driven by
ncreased release of cytokines, e.g., interleukins (IL-1, IL-6,
L-18) and tumor necrosis factor-alpha, which themselves also
redict cardiovascular risk (42–45). Hence, cardiovascular risk
ould be reduced by treatments that have direct anti-
nflammatory effects. In contrast, ACS is associated with low
irculating levels of the anti-inflammatory cytokines, e.g.,
L-10, and recent observations suggest that high IL-10 levels
ttenuate the risk associated with an elevated CRP (46),
eflecting a dynamic relationship between pro-inflammatory
nd anti-inflammatory processes. Another emerging prognos-
ic marker also elevated in ACS is CD40-ligand (47), which
as been shown to regulate plaque stability (48), and its
otential modulation could be an important target for future
ystemic therapy.
ODULATION OF INFLAMMATION BY STATINS
ecently, statins have been shown to directly bind to
eceptors on the lymphocyte cell surface (lymphocyte func-
ion associated antigen), preventing binding to the counter-
eceptor on the endothelial surface (ICAM-1) (49). Addi-
ionally, statins reduce the production of chemoattractants
e.g., MCP-1) by the vessel wall. These direct anti-
nflammatory effects are important and distinct from effects on
DL-C, and result in a reduction in the net number of
nflammatory cells within plaques (50). In addition, statins
lin; ICAM  intercellular adhesion molecule; NO  nitric oxide; PAI 
sue factor; TM  thrombomodulin; VCAM  vascular cellular adhesiondotheeduce the activation of the monocyte/macrophage system,
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Lipid-Independent Effects of Statins in ACS October 18, 2005:1425–33esulting in a reduction in the release of proteolytic enzymes
matrix metalloproteinases) (51). Statins also have many favor-
ble effects on T-lymphocytes, which include reducing their
ytotoxicity (52). T-helper cell subclasses that promote inflam-
ation (Th-1 subclass) are inhibited by statins. In contrast,
-helper subclasses that promote anti-inflammatory effects
Th-2 subclass) are stimulated by statins (53), resulting in a net
switching” of cytokine production among T-cells from the
roduction of pro-inflammatory cytokines such as interferon-
amma to the production of anti-inflammatory cytokines such
s IL-4 or IL-10 (54). The net result of these effects would be
o promote plaque stabilization (Table 3). Statins diminish the
roinflammatory activity of monocytes (55) and their ability to
ind to the vessel wall. The latter is mediated by a reduction in
he expression of endothelial adhesion molecules such as
CAM-1 on the endothelial surface and their counter ligand
CD11a/CD18) on the monocyte (56), which are dependent
n the Rho/Rho kinase pathways. Hence, statins modify the
mmune response in ACS via reductions in inflammatory cell
umber, adhesion, and activation at potentially vulnerable sites
long the wall.
Statins reduce the production and release of cytokines
nvolved in the inflammatory cascade (IL-6, IL-8, tumor
ecrosis factor-alpha, and CD40 ligand) (57), and thus
educe CRP independently of their effects on LDL-C.
igure 4. Inflammatory changes in acute coronary syndrome. CRP  C
hemoattractant protein; MMP  matrix metalloproteinases; MPO  m-reactive protein has a number of direct pathological Affects on atherosclerosis progression (4), endothelial dys-
unction (58), and thrombosis (59). Hence, by lowering
RP, statins potentially negate many of the pathological
ffects of inflammation.
Cholesterol rafts are cholesterol-rich regions of the cell
embrane where many receptors involved in cell signaling
referentially accumulate. A novel and increasingly recog-
ized effect of statins is their ability to deplete the lipid
ctive protein; IFN  interferon; IL  interleukin; MCP  monocyte
roxidase; TNF  tumor necrosis factor. Illustration by Rob Flewell.
able 3. Inflammatory Changes Implicated in ACS and the
ffect of Statins on Components of Inflammation
Changes
Implicated
in ACS
Effect of
Statins
hanges within the plaque
Inflammatory cells infilltrate plaque 1 2
Inflammatory cells activated 1 2
ystemic effects
T-cell activation 1 2
Monocyte activation 1 2
Neutrophil activation 1 2
ytokine production
Inflammatory cytokine production 1 2
Anti-inflammatory cytokine production 2 1
on-specific markers of inflammation
CRP 1 2
schemia/reperfusion injury 1 2bbreviations as in Table 1.
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October 18, 2005:1425–33 Lipid-Independent Effects of Statins in ACSontent of cholesterol rafts and thus alter their function,
esulting in reduced inflammatory signaling (60). Other
nown beneficial anti-inflammatory effects of statins include
educing ischemia reperfusion injury and infarct size in
nimal and clinical models (61) (Table 3).
mmune modulation in non-vascular disease. In addition
o benefits in vascular disease, there is now evidence that
tatins improve non-vascular diseases that have an inflam-
atory etiology. In relapsing-remitting multiple sclerosis,
igh-dose statin therapy reduced gadolinium-enhancing
esions at four to six months on magnetic resonance imaging
cans (62). In animal models of relapsing-remitting enceph-
lomyelitis, the use of statin therapy reversed or prevented
hronic and relapsing paralysis (63). These beneficial effects
ere associated with beneficial effects on immunomodula-
ion (cytokine switching). In patients with rheumatoid
rthritis receiving disease-modifying drugs, statins reduced
isease activity scores by 21% at six months (64), which
oincided with a 50% reduction in CRP. In observational
tudies, statin use is associated with a 60% to 73% lower
ncidence of Alzheimer disease (65). Although the mecha-
isms are unclear, it is speculated that reductions in neuro-
al levels of a peptide implicated in Alzheimer disease
Abeta42) may play a role (66). These data in the setting of
on-vascular disease provide even more compelling evidence
hat statins possess LDL-C–independent effects that be-
ome clinically relevant within a relatively short time
indow.
TATIN SOLUBILITY AND DOSE
he solubility of a statin could potentially influence the
agnitude of the LDL-C–independent effects. In particu-
ar, hydrophilic statins have been associated with an increase
n the collagen and smooth muscle cell content in athero-
clerotic lesions compared with lipophilic statins in animal
odels of atherosclerosis (50). However, lipophilic statins
ere superior to hydrophilic statins in the ability to reduce
ytokine production in endothelial and inflammatory cells
ia inhibition of Rho (21). Differences in lipid-independent
ffects between statins possibly resulting from drug solubil-
ty have been suggested by recent clinical studies (67). A
ose-dependent relationship for the inhibition of Rho-
ediated lipid-independent effects exists in vitro. We would
herefore predict that higher doses of a lipophilic statin
ould be associated with the greatest as well as the most
apid effect in vascular cells. Whether there are differences
etween statins based on solubility that are of biological and
linical relevance warrants further study.
VIDENCE FROM CLINICAL TRIALS
everal trials have investigated the effects of statins in ACS.
he first of these (MIRACL) showed that atorvastatin 80
g reduced clinical events and CRP at four months
ompared with placebo (68,69). A trend toward a reduction
n soluble CD40-ligand was also observed with atorvastatin0 mg. In the PROVE IT-TIMI 22 trial, atorvastatin 80
g lowered CRP at 30 days compared with pravastatin 40
g, and this was associated with clinically significant benefit
y four months (70,71). In contrast, in patients with stable
AD, benefit is delayed. Inspection of the Kaplan-Meier
urves shows little detectable separation in the first year
Scandanavian Simvastatin Survial Study [4S] and Long-
erm Intervention with Pravastatin in Ischemic Disease
LIPID] study) (3) or two years (Cholesterol And Recur-
ent Events [CARE] trial) (3). These differences suggest
hat the clinical benefits of intensive statin therapy observed
n ACS patients occurred very early, and perhaps before the
reater reductions in LDL-C were likely to have had any
ignificant effect on disease progression.
Two recent publications have intensified the debate about
hoice and dose of statin in ACS. The Pravastatin in Acute
oronary Teatment [PACT] study investigated the use of
ravastatin 20 to 40 mg versus placebo within 24 hours of
on–ST-segment elevation ACS at 30 days. There seemed
o be no difference between the pravastatin 20 mg group and
lacebo, but benefit tended to be seen only in the pravastatin
0 mg group, in an overall negative trial. In the recent Z
hase of the A to Z study, simvastatin 40 mg failed to lower
RP at one month compared with placebo, and in turn no
ignificant clinical benefit was observed within the first four
onths after randomization. This suggests that the highest
tatin doses may be important for early clinical benefits in
CS patients.
UMMARY
cute coronary syndrome is accompanied by adverse
hanges in inflammation, the immune system, endothelial
unction, and coagulation, which may be causative or
piphenomena. Statins improve adverse biological profiles
apidly in a dose-dependent manner in vitro and in animal
tudies, and thus the lipid-independent effects of statins
ay contribute to the early reduction in cardiovascular risk
bserved with intensive statin therapy in ACS patients.
hese observed biological effects deserve further study in
atients regarding the role of statin type and dose, and may
pen up new avenues beyond statin therapy for other more
otent and specific inhibitors of the pathways impacted by
tatins, as new ways of improving outcomes in ACS.
eprint requests and correspondence: Dr. Kausik K. Ray, The
IMI Study Group, 350 Longwood Avenue, 1st Floor, Boston
assachusetts 02115. E-mail: kkray@partners.org.
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